Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) and SynWorld Technologies have mutually terminated the Canalevia Agreement, effective January 31, 2023. This agreement, initiated in June 2022, focused on the treatment of diarrhea in dogs within the Chinese market.
Jaguar is redirecting its efforts towards human drug development, specifically the OnTarget trial for cancer therapy-related diarrhea and further research on rare diseases. CEO Lisa Conte expressed that this shift aims to enhance value creation within the next six months. While both companies may explore future opportunities, geopolitical factors will influence any potential collaboration related to Canalevia.
Jaguar Health (NASDAQ:JAGX) has entered a service agreement with Shareholder Intelligence Services, LLC to track market participants and analyze share ownership data. This collaboration aims to combat illegal short selling, which can depress stock prices and harm investor interests. According to CEO Lisa Conte, this initiative is vital for maximizing shareholder value and ensuring compliance with SEC and FINRA regulations. ShareIntel's platform will assist in identifying potential illegal practices in trading, thereby promoting transparency and effective price discovery for Jaguar's stock.
Jaguar Health, Inc. (NASDAQ:JAGX) has appointed Andrew Mulberg, M.D., former FDA Deputy Director, as a regulatory consultant to enhance its regulatory strategy. Dr. Mulberg, noted for his role in approving Jaguar's crofelemer, will support the company’s focus on ongoing clinical trials, including a Phase 3 study for cancer therapy-related diarrhea. This appointment aims to leverage Dr. Mulberg's extensive regulatory expertise to facilitate future access to crofelemer, a plant-based treatment for various gastrointestinal disorders. Jaguar Health continues to develop non-opioid medicines for serious gastrointestinal conditions while ensuring sustainability in its production processes.
Jaguar Health (NASDAQ:JAGX) announced the grant of 7,500 restricted stock units (RSUs) each to two new employees, effective January 19, 2023. Post-reverse stock split on January 23, 2023, this will equal 100 RSUs per employee. The RSUs vest over three years, contingent upon continued employment. This grant was approved by the Compensation Committee as an inducement for the new hires. Jaguar Health focuses on plant-based, non-opioid medicines for gastrointestinal distress.
Jaguar Health (NASDAQ:JAGX) has announced its strategic focus on rare disease treatments through its subsidiary, Napo Therapeutics. The company intends to submit an Investigational New Drug (IND) application for crofelemer targeting microvillus inclusion disease (MVID) in the first half of 2023, following previous orphan drug designations for both MVID and short bowel syndrome (SBS). Jaguar anticipates significant developments for its NP-300 drug for cholera treatment, including pursuing a Tropical Disease Priority Review Voucher. The firm is optimistic about upcoming clinical trials and their potential impact on shareholder value.
Jaguar Health (NASDAQ:JAGX) announced a significant milestone in the development of crofelemer, an active pharmaceutical ingredient (API) now approved for manufacturing by Indena S.P.A. This completion allows for increased production capabilities as Jaguar seeks FDA approval for new indications, specifically for cancer therapy-related diarrhea. Patient enrollment for the pivotal Phase 3 OnTarget clinical trial is expected to conclude in Q2 2023. This achievement is positioned to meet the anticipated surge in demand for crofelemer, highlighting the collaboration between Jaguar and Indena, a leader in plant-based pharmaceuticals.
Jaguar Health, Inc. (NASDAQ:JAGX) has established the board of directors for its newly formed joint venture, Magdalena Biosciences, Inc., created with Filament Health Corp. (NEO:FH, OTCQB:FLHLF). The joint venture aims to develop natural prescription medicines targeting mental health issues, including ADHD in adults. Dr. Karen Brunke has been appointed as the acting CEO of Magdalena. Board members include Jaguar's CEO Lisa Conte and Filament's CEO Benjamin Lightburn, both bringing extensive experience in biotechnology and pharmaceuticals. This initiative intends to leverage plant-derived therapies for mental health, aligning with Jaguar's mission.
Jaguar Health announced the approval of a 1-for-75 reverse stock split effective January 23, 2023, to comply with Nasdaq listing standards. Following the split, shares will be traded on a split-adjusted basis under the stock symbol JAGX. The decision was supported by a majority vote at the Special Meeting of Stockholders held on January 20, 2023. Additionally, the company expects to complete enrollment for its pivotal Phase 3 OnTarget clinical trial by Q2 2023, focusing on crofelemer for cancer therapy-related diarrhea. This trial is part of Jaguar's growth strategy amidst two key late-stage clinical activities anticipated to drive value creation.
Jaguar Health (NASDAQ:JAGX) announced on January 20, 2023, that CEO Lisa Conte will present at the virtual Lytham Partners Investor Select Conference on January 31, 2023. The presentation begins at 9:00 a.m. Eastern Time and will be available for online viewing. Interested parties can access the webcast here, and it will also be archived for replay.
Management will hold virtual one-on-one meetings during the event, arranged through Lytham Partners. Jaguar Health focuses on developing plant-based prescription medicines for gastrointestinal issues.
Jaguar Health has announced the addition of Dr. Sandra M. Swain to its Scientific Advisory Board. Dr. Swain, an internationally recognized physician with over 30 years of experience, will enhance Jaguar's clinical development efforts aimed at addressing cancer therapy-related diarrhea (CTD). She is known for her role in the HALT-D trial, demonstrating the need for effective CTD management. This move is expected to bolster Jaguar's ongoing Phase 3 trial, OnTarget, focused on the prophylaxis of diarrhea in cancer patients.